I have been under Dr Verter's care for a couple years after a torn retina. He and his team in Westport have been rockstars! Kudos to all!!! 👏👏👏👏
Understanding Your Macular Degeneration Treatment Options
What Is Age-Related Macular Degeneration
Age-related macular degeneration (AMD) is a condition that damages the macula, the small central area of the retina (the light-sensitive tissue lining the back of the eye). The macula is responsible for sharp, detailed central vision. When it breaks down, you may notice blurriness, dark spots, or distortion in the center of your visual field.
Nearly 20 million adults in the United States live with some form of AMD (BrightFocus Foundation, 2025). Worldwide, the number is expected to reach 288 million by 2040 (Lancet Global Health, 2014). AMD is one of the leading causes of vision loss in people over age 50, making early detection and treatment especially important.
There are two main forms of AMD. Dry AMD is the more common type, accounting for the large majority of all cases. It develops when small yellow deposits called drusen accumulate under the retina and gradually thin the macular tissue. Vision loss from dry AMD tends to progress slowly over months or years.
Wet AMD, also called neovascular AMD, is less common but more aggressive. It occurs when abnormal blood vessels grow beneath the retina and leak fluid or blood. This leaking can cause rapid and significant central vision loss if not treated promptly. Your retina specialist can determine which form of AMD you have through a comprehensive dilated eye exam and imaging tests.
Geographic atrophy (GA) is the advanced stage of dry AMD. In GA, cells in the retinal pigment epithelium (the support layer beneath the retina) gradually die off, creating expanding areas of tissue loss. This leads to progressive blind spots that can grow larger over time.
Until recently, there were no approved treatments for geographic atrophy. Fortunately, new medications now offer ways to slow the progression of GA, giving patients more options than supportive care alone.
Treatments for Wet AMD
The primary treatment for wet AMD involves intravitreal injections, which are medications delivered directly into the eye. These drugs target a protein called vascular endothelial growth factor (VEGF). VEGF signals the body to grow new blood vessels, but in wet AMD, this process goes wrong and produces fragile, leaky vessels under the retina.
Anti-VEGF medications block this protein, helping to stop abnormal vessel growth and reduce fluid leakage. Research from the AAO IRIS Registry, which analyzed over 254,000 eyes, shows that anti-VEGF therapy typically produces meaningful vision improvement within the first year of treatment (AAO, 2024). Approximately 90 percent of treated eyes achieve stabilized or improved vision (MDPI Pharmaceuticals, 2023).
Several anti-VEGF drugs are approved for treating wet AMD. Your retina specialist will choose the medication best suited to your condition and treatment goals. Each drug works by a similar mechanism but may differ in dosing schedule and molecular structure.
- Eylea (aflibercept) is one of the most widely used anti-VEGF agents. It may be given every four to eight weeks after initial monthly loading doses.
- Eylea HD (high-dose aflibercept) is an updated formulation approved in 2023. Its higher concentration may allow for longer intervals between injections.
- Lucentis (ranibizumab) was one of the first anti-VEGF drugs specifically designed for eye use. It is typically administered monthly or on a treat-and-extend schedule.
- Avastin (bevacizumab, used off-label) was originally developed for cancer treatment. Clinical studies have shown it to be similarly effective to other anti-VEGF agents for wet AMD at a lower dosing volume.
- Vabysmo (faricimab) is a newer bispecific antibody that targets both VEGF and a second protein called angiopoietin-2. This dual action may help extend treatment intervals for some patients.
- Beovu (brolucizumab) is another option that may allow longer intervals between injections. Your retina specialist will discuss whether this medication is appropriate for you.
Receiving an intravitreal injection may sound intimidating, but the procedure is quick and typically well tolerated. Your retina specialist will first numb your eye with anesthetic drops. The surface of your eye will be cleaned with an antiseptic solution to reduce infection risk.
The injection itself takes only a few seconds. A very fine needle delivers a tiny amount of medication into the vitreous gel inside your eye. Most patients report feeling mild pressure rather than sharp pain. You may notice floaters or slight blurriness for a day or two afterward, which typically resolves on its own.
Anti-VEGF treatment for wet AMD is not a one-time procedure. Most patients require ongoing injections to keep the disease under control. Your retina specialist may start with monthly injections for the first three months, then adjust the schedule based on how your eye responds.
A common approach is called 'treat and extend,' where your specialist gradually lengthens the time between injections as long as your retina remains stable. Data from the AAO IRIS Registry shows that patients who received more frequent injections in the first year tended to achieve better long-term vision outcomes (AAO, 2024). Staying consistent with your treatment schedule is one of the most important things you can do to protect your vision.
Treatments for Geographic Atrophy
Geographic atrophy, the advanced form of dry AMD, now has two FDA-approved treatment options. Both belong to a class of drugs called complement inhibitors. They work by targeting the complement system, a part of the immune system that, when overactive, contributes to the progressive cell death seen in GA.
These medications do not restore lost vision. Instead, they are designed to slow the rate at which geographic atrophy lesions grow. By reducing the speed of tissue loss, complement inhibitors aim to preserve your remaining vision for a longer period.
Syfovre (pegcetacoplan) is a complement inhibitor that targets complement component C3. It became the first FDA-approved treatment for geographic atrophy in February 2023. Syfovre is delivered through intravitreal injection, either monthly or every other month.
Clinical trial data showed that monthly treatment with Syfovre reduced the rate of GA lesion growth by 31 percent compared to observation alone, while every-other-month dosing achieved a 25 percent reduction (FDA, 2023). At 36 months, patients receiving monthly treatment also demonstrated better preservation of visual function on specialized testing (Retinal Physician, 2025).
Izervay (avacincaptad pegol) is a complement inhibitor that targets complement component C5. It received FDA approval in August 2023. Like Syfovre, it is administered through intravitreal injection.
At 24 months, Izervay demonstrated a meaningful reduction in GA lesion growth compared to observation. Extended follow-up data from the GATHER2 clinical trial showed that monthly dosing sustained reductions in lesion growth for as long as three and a half years (Astellas Pharma, 2025). Your retina specialist can help you understand which complement inhibitor, if either, may be right for your situation.
Monitoring and Diagnostic Tools
Optical coherence tomography (OCT) is one of the most valuable tools your retina specialist uses to monitor AMD. This noninvasive imaging test uses light waves to create detailed cross-sectional pictures of your retina. It can detect fluid, swelling, or thinning that may not be visible during a standard eye exam.
OCT scans take only a few minutes and require no injections or dilation in many cases. Your specialist will likely perform OCT at every visit to track how your retina responds to treatment and to decide whether to continue, adjust, or extend your injection schedule.
Fluorescein angiography (FA) is another important diagnostic test. During this procedure, a special dye is injected into a vein in your arm. As the dye travels through the blood vessels in your retina, a camera captures images that reveal any leaking or abnormal blood vessels.
This test is particularly useful when your retina specialist first diagnoses wet AMD or suspects that dry AMD may be converting to the wet form. It provides a detailed map of blood vessel activity that helps guide treatment decisions. The dye is generally well tolerated, though some patients experience temporary nausea or skin discoloration.
Between office visits, your retina specialist may recommend daily self-monitoring with an Amsler grid. This simple tool is a square grid pattern with a dot in the center. You look at it one eye at a time and note whether any lines appear wavy, broken, or missing.
Changes on the Amsler grid can be an early sign that your AMD is progressing or that new fluid is developing. If you notice sudden changes, contact your retina specialist promptly. Early detection of changes can make a meaningful difference in treatment outcomes.
Lifestyle and Supportive Strategies
The Age-Related Eye Disease Study (AREDS2) found that a specific combination of vitamins and minerals can reduce the risk of intermediate dry AMD progressing to the advanced stage. The AREDS2 formula includes vitamins C and E, lutein, zeaxanthin, zinc, and copper (NEI, 2013).
Your retina specialist can advise you on whether the AREDS2 supplement is appropriate for your stage of AMD. These supplements are not a substitute for medical treatment, but they may provide additional protection for patients with intermediate disease. A diet rich in leafy green vegetables, fish, and colorful fruits also supports overall retinal health.
Ultraviolet (UV) light exposure is considered a modifiable risk factor for AMD. Wearing sunglasses that block both UVA and UVB rays can help protect your retinas when you are outdoors. Wide-brimmed hats provide additional shading.
A substantial portion of UV radiation can penetrate cloud cover, so eye protection is beneficial even on overcast days. Your retina specialist may also recommend photochromic lenses or specific tints that reduce glare and improve contrast sensitivity if you are already experiencing vision changes from AMD.
Smoking is one of the most significant controllable risk factors for developing and worsening AMD. Studies consistently show that smokers have a substantially higher risk of progression compared to nonsmokers. If you currently smoke, quitting is one of the most impactful steps you can take for your eye health.
Maintaining a healthy weight, managing cardiovascular risk factors such as high blood pressure and high cholesterol, and engaging in regular physical activity are also associated with better outcomes. These strategies complement your medical treatment and support long-term retinal health.
Understanding Your Treatment Journey
One of the most important aspects of AMD treatment is understanding what current therapies can and cannot do. For wet AMD, anti-VEGF injections can stabilize or improve vision in many patients, particularly when started early. However, results vary based on the severity of the disease at diagnosis and how consistently treatment is maintained.
For geographic atrophy, complement inhibitors aim to slow the rate of tissue loss rather than reverse damage that has already occurred. The goal is to preserve as much functional vision as possible over time. Your retina specialist will work with you to establish realistic goals and monitor your progress at each visit.
Research shows that treatment consistency is closely linked to visual outcomes. Data from large registry studies indicate that patients who attend regular appointments and maintain their injection schedules tend to retain better vision over time (AAO, 2024). Missing appointments or delaying treatment can allow the disease to progress between visits.
Your retina specialist will create a personalized treatment plan that balances effectiveness with convenience. If you find it difficult to keep up with your schedule due to transportation, mobility, or other challenges, discuss these concerns with your care team. They may be able to suggest solutions or adjust your plan accordingly.
AMD is a chronic condition, and your treatment plan may evolve over time. Your retina specialist may switch medications if your current therapy is not producing the desired response. They may also adjust injection intervals based on how your retina looks on imaging.
In some cases, dry AMD can convert to the wet form, which is called neovascular conversion. This is why regular monitoring is critical even if your vision seems stable. If neovascular conversion occurs, your specialist will begin appropriate treatment promptly to limit vision loss.
Emerging Research and Future Directions
Researchers are exploring several promising approaches to improve AMD treatment. Gene therapy aims to enable retinal cells to produce their own anti-VEGF proteins, which could potentially reduce or eliminate the need for repeated injections. Several clinical trials are currently evaluating gene therapy approaches for wet AMD.
Sustained-release drug delivery systems, such as refillable implants placed inside the eye, represent another area of active development. These devices are designed to release medication slowly over months, reducing the burden of frequent office visits while maintaining consistent drug levels in the eye.
Scientists are investigating medications that target pathways beyond VEGF and complement. Some experimental therapies address inflammation, oxidative stress, or cell death pathways involved in AMD progression. Combination treatments that target multiple pathways simultaneously are also being studied.
While these investigational therapies are not yet available for routine clinical use, they reflect a growing understanding of AMD biology. Your retina specialist can discuss whether you might be eligible for any clinical trials exploring these newer approaches.
Common Questions About Macular Degeneration Treatment
Most patients are pleasantly surprised by how comfortable intravitreal injections are. Your retina specialist numbs the eye thoroughly before the procedure, and the injection itself lasts only a few seconds. You may feel brief pressure, but significant pain is uncommon. Mild soreness or a gritty sensation afterward typically resolves within a day.
For wet AMD, most patients require ongoing treatment to keep the disease under control. Some patients may eventually extend intervals significantly or reach a point of stability, but AMD is a chronic condition that requires long-term monitoring. For geographic atrophy, complement inhibitor treatment is also ongoing, with regular injections intended to slow lesion growth over time. Your retina specialist will reassess your plan at each visit.
Treatment significantly reduces the risk of severe vision loss, but AMD can still progress despite therapy. The goal of treatment is to preserve as much vision as possible for as long as possible. Starting treatment early and maintaining a consistent schedule gives you the best chance of a favorable outcome. If you notice sudden vision changes between appointments, contact your retina specialist right away.
Your retina specialist will provide specific instructions after each injection. In general, you should avoid rubbing your eye for the rest of the day. Swimming pools, hot tubs, and other bodies of water should be avoided for a few days to reduce infection risk. Most patients can return to their normal daily activities, including reading and watching television, the same day.
Neovascular conversion, when dry AMD transitions to the wet form, can happen at any stage. This is why regular monitoring visits are so important, even if your vision seems stable. If conversion occurs, your retina specialist will begin intravitreal injection therapy to address the new abnormal blood vessels. Early detection through routine imaging and home monitoring with the Amsler grid can help catch this transition quickly, leading to better treatment outcomes.
30 Years of Care & Commitment
